Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019649 | 1.00 | PLG (0.49) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL15037348 | 1.00 | PLG (0.49) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL15019646 | 1.00 | PLG (0.49) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL16306210 | 0.97 | PLG (0.47) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL16305825 | 0.93 | GCGR (0.52) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL15019653 | 0.93 | GCGR (0.52) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL16380079 | 0.93 | GCGR (0.52) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL15019651 | 0.93 | GCGR (0.52) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL16305921 | 0.93 | GCGR (0.52) | PLGL3MBTL1KLKB1PPARGPPARA | |
| SCHEMBL15037414 | 0.93 | PLG (0.51) | PLGL3MBTL1KLKB1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9187522-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150038416-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-02-05 | — | — | US | disclosed |
| US-20150038416-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-02-05 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| WO-2014201172-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778923-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013090454-A2 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885L3MBTL1 771/4885KLKB1 2855/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885L3MBTL1 771/4885KLKB1 2855/4885 |
| US-20130178420-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3214/4885L3MBTL1 728/4885KLKB1 2819/4885 |
| US-20150038416-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3214/4885L3MBTL1 728/4885KLKB1 2819/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | PLG 2930/4885L3MBTL1 579/4885KLKB1 2865/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | PLG 2930/4885L3MBTL1 579/4885KLKB1 2865/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885L3MBTL1 771/4885KLKB1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.